Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial brillation. Chest. 2001;119( suppl 1):194S-206S. 32. Wang TJ, Massaro JM, Levy D, et al. A risk score for pre- dicting stroke or death in individuals with new-onset atrial brillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049-1056. 33. van Walraven C, Hart RG, Wells GA, et al. A clinical pre- diction rule to identify patients with atrial brillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163(8):936-943. 34. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial brillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):429S-456S. 35. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk strati cation of patients with atrial brillation. Stroke. 2006;37(9):2294-2300. 36. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Re ning clinical risk strati cation for predicting stroke and thromboembolism in atrial brillation using a novel risk factor-based approach: the euro heart survey on atrial bril- lation. Chest. 2010;137(2):263-272. 37. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial brillation for anticoagulation: stroke risk strati cation in patients taking aspirin. Circulation. 2004;110(16):2287-2292. 38. Baruch L, Gage BF, Horrow J, et al. Can patients at ele- vated risk of stroke treated with anticoagulants be further risk strati ed? Stroke. 2007;38(9):2459-2463. 39. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE; ATRIA Study Group. Comparison of risk strat- i cation schemes to predict thromboembolism in people with nonvalvular atrial brillation. J Am Coll Cardiol. 2008;51(8):810-815. 40. 